This audio is generated automatically. Please let me know if you have any comments.
Ingredients in Focus is Food Dive's bite-sized column highlighting exciting developments in the ingredients sector.
Israeli biotechnology company Miletus and Yotvata Dairy join forces. To develop Miletus' Imilac product as an antibiotic alternative for milk products.
Under Agreement, Yacht Bata Money will be invested to improve the management systems of dairy farms. Although financial details were not disclosed, the agreement includes a prototype of a “state-of-the-art dairy farm management system” that will serve as a model for operating a commercial dairy farm without antibiotics.
The investment comes after Miletus completed clinical trials that “proven the effectiveness” of the product in increasing milk volume and production. The trial involved more than 500 cows from seven large dairy farms in Israel, the company said.
“Dairy companies around the world are beginning to recognize that Miletis’ innovative solutions are poised to advance the industry toward a more sustainable future, benefiting consumers, dairy farmers and animals alike,” said Miletis CEO and co-founder. “The agreement with Yotvata is another milestone towards our vision of leading the dairy industry towards a sustainable future as it faces significant challenges,” said David Javier Iscovich.
Antibiotics in milk and dairy products are used to prevent disease, promote growth, and treat mastitis. However, they are also found to be: Causes problems for consumers and milk processorsAccording to the National Institutes of Health.
These include cancer and hypersensitivity reactions along with the development of antibiotic resistance.
Miletus said its product reduces greenhouse gas emissions by increasing milk production per cow. According to the company, 90% of the largest dairy processing companies have set a goal to become carbon neutral by 2050. Miletus added that the additional milk produced by Imilac helps dairy farmers' productivity and profitability.
